Cabaletta Bio Statistics
Total Valuation
Cabaletta Bio has a market cap or net worth of $204.56 million. The enterprise value is $75.71 million.
Important Dates
The last earnings date was Monday, November 10, 2025, before market open.
| Earnings Date | Nov 10, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Cabaletta Bio has 96.27 million shares outstanding. The number of shares has increased by 36.24% in one year.
| Current Share Class | 96.27M |
| Shares Outstanding | 96.27M |
| Shares Change (YoY) | +36.24% |
| Shares Change (QoQ) | +65.27% |
| Owned by Insiders (%) | 1.57% |
| Owned by Institutions (%) | 54.87% |
| Float | 71.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.59 |
| P/TBV Ratio | 1.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.60, with a Debt / Equity ratio of 0.18.
| Current Ratio | 3.60 |
| Quick Ratio | 3.50 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -74.38 |
Financial Efficiency
Return on equity (ROE) is -101.06% and return on invested capital (ROIC) is -57.59%.
| Return on Equity (ROE) | -101.06% |
| Return on Assets (ROA) | -51.82% |
| Return on Invested Capital (ROIC) | -57.59% |
| Return on Capital Employed (ROCE) | -113.46% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$966,604 |
| Employee Count | 164 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +14.44% in the last 52 weeks. The beta is 3.14, so Cabaletta Bio's price volatility has been higher than the market average.
| Beta (5Y) | 3.14 |
| 52-Week Price Change | +14.44% |
| 50-Day Moving Average | 2.49 |
| 200-Day Moving Average | 1.86 |
| Relative Strength Index (RSI) | 42.82 |
| Average Volume (20 Days) | 5,128,181 |
Short Selling Information
The latest short interest is 12.95 million, so 13.45% of the outstanding shares have been sold short.
| Short Interest | 12.95M |
| Short Previous Month | 11.22M |
| Short % of Shares Out | 13.45% |
| Short % of Float | 18.17% |
| Short Ratio (days to cover) | 2.14 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -163.42M |
| Pretax Income | -158.52M |
| Net Income | -158.52M |
| EBITDA | -161.65M |
| EBIT | -163.42M |
| Earnings Per Share (EPS) | -$2.41 |
Full Income Statement Balance Sheet
The company has $159.93 million in cash and $25.78 million in debt, giving a net cash position of $134.15 million or $1.39 per share.
| Cash & Cash Equivalents | 159.93M |
| Total Debt | 25.78M |
| Net Cash | 134.15M |
| Net Cash Per Share | $1.39 |
| Equity (Book Value) | 139.47M |
| Book Value Per Share | 1.45 |
| Working Capital | 118.83M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$118.86 million and capital expenditures -$1.40 million, giving a free cash flow of -$120.26 million.
| Operating Cash Flow | -118.86M |
| Capital Expenditures | -1.40M |
| Free Cash Flow | -120.26M |
| FCF Per Share | -$1.25 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Cabaletta Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -36.24% |
| Shareholder Yield | -36.24% |
| Earnings Yield | -75.54% |
| FCF Yield | -57.30% |
Analyst Forecast
The average price target for Cabaletta Bio is $13.50, which is 535.29% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $13.50 |
| Price Target Difference | 535.29% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -32.55% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |